https://scholars.lib.ntu.edu.tw/handle/123456789/189628
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor | 內科 | en |
dc.contributor.author | YU, CHONG-JEN | en |
dc.creator | 余忠仁;陳育民 | zh-tw |
dc.creator | YU, CHONG-JEN;CHEN, YUH-MIN | en |
dc.date | 2009 | en |
dc.date.accessioned | 2010-06-21T08:16:36Z | - |
dc.date.accessioned | 2018-07-11T06:18:40Z | - |
dc.date.available | 2010-06-21T08:16:36Z | - |
dc.date.available | 2018-07-11T06:18:40Z | - |
dc.date.issued | 2009 | - |
dc.identifier.uri | http://ntur.lib.ntu.edu.tw//handle/246246/185808 | - |
dc.description.abstract | Purpose This study investigated whether sequential administration of erlotinib and chemotherapy improves clinical outcomes versus chemotherapy alone in unselected, chemotherapy-naive patients with advanced non-small- cell lung cancer (NSCLC). Patients and Methods Previously untreated patients (n = 154) with stage IIIB or IV NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomly assigned to receive erlotinib (150 mg/d) or placebo on days 15 to 28 of a 4-week cycle that included gemcitabine (1,250 mg/m(2) days 1 and 8) and either cisplatin (75 mg/m2 day 1) or carboplatin (5 x area under the serum concentration-time curve, day 1). The primary end point was nonprogression rate (NPR) at 8 weeks. Secondary end points included tumor response rate, NPR at 16 weeks, duration of response, progression-free survival (PFS), overall survival (OS), and safety. Results The NPR at 8 weeks was 80.3% in the gemcitabine plus cisplatin or carboplatin (GC)-erlotinib arm (n = 76) and 76.9% in the GC- placebo arm (n = 78). At 16 weeks, the NPR was 64.5% for GC - erlotinib versus 53.8% for GC-placebo. The response rate was 35. 5% for GC-erlotinib versus 24.4% for GC-placebo. PFS was significantly longer with GC-erlotinib than with GC- placebo(adjusted hazard ratio, 0.47 ; log-rank P = .0002; median, 29.4 v 23.4 weeks); this benefit was consistent across all clinical subgroups. There was no significant difference in OS. The addition of erlotinib to chemotherapy was well tolerated, with no increase in hematologic toxicity , and no treatment- related interstitial lung disease. Conclusion Sequential administration of erlotinib following gemcitabine/platinum chemotherapy led to a significant improvement in PFS. This treatment approach warrants further investigation in a phase III study. | en |
dc.language | en-us | en |
dc.language.iso | en_US | - |
dc.relation | JOURNAL OF CLINICAL ONCOLOGY v.27 n.30 pp.5080-5087 | en |
dc.relation.ispartof | JOURNAL OF CLINICAL ONCOLOGY | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.title | Randomized, Placebo-Controlled, Phase Ii Study of Sequential Erlotinib and Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer | en |
dc.type | journal article | en |
dc.relation.pages | 5080-5087 | - |
dc.relation.journalvolume | v.27 | - |
dc.relation.journalissue | n.30 | - |
item.languageiso639-1 | en_US | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。